• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Propanc Gives Update on PRP Study

    Bryan Mc Govern
    May. 02, 2017 09:08AM PST
    Pharmaceutical Investing

    Propanc Biopharma provided an update on the development of the GMP-compliant investigational medicinal product (IMP) manufacture of PRP for First-In-Human studies.

    Propanc Biopharma (OTCQB:PPCHD) provided an update on the development of the GMP-compliant investigational medicinal product (IMP) manufacture of PRP for first-in-human studies.
    As quoted in the press release:

    PRP is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
    Both proenzymes have been successfully isolated from natural sources to a defined quality and will be purified further to GMP standards to obtain the final IMP. The isolation processes for both proenzymes have been established and scaled up to commercial size quantities. These freeze dried isolates will serve as starting materials for the Good Manufacturing Practice (GMP) manufacturing processes, which are currently under development for both proenzymes by the Company’s manufacturing partner, Q Biologicals, in Ghent, Belgium.
    In order to define the optimal purification process, the starting materials were characterized for identity and impurities in the laboratories of Professor Buchner, Chair of Biotechnology, from the Technical University of Munich. Furthermore, analytical methods to initially determine and then control the quality of the starting materials are nearly fully established and specifications defined to ensure a consistent quality of IMP.

    Click here to read the full press release.

    pharmaceutical investingpropanc biopharmapancreatic proenzymes trypsinogen
    The Conversation (0)

    Go Deeper

    AI Powered
    Praxis Precision Medicines to Participate in Upcoming Investor Conferences

    Praxis Precision Medicines to Participate in Upcoming Investor Conferences

    Sirona Biochem Eyes 2025 Launch of New Anti-aging Product

    Sirona Biochem Eyes 2025 Launch of New Anti-aging Product

    Latest News

    Appendix 4E and Annual Report

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×